Biosimilars: is interchangeability the proof of the pudding?

Med J Aust. 2021 Feb;214(3):124-125. doi: 10.5694/mja2.50912. Epub 2021 Jan 6.
No abstract available

Keywords: Inflammatory bowel diseases.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Australia
  • Biosimilar Pharmaceuticals*
  • Cohort Studies
  • Humans
  • Inflammatory Bowel Diseases*
  • Infliximab

Substances

  • Biosimilar Pharmaceuticals
  • Infliximab